Brian M. Maas

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

Antonios O. Aliprantis, Dennis Wolford, Luzelena Caro et al. · Clinical Pharmacology in Drug Development · 2020 · 64 citations

Pharmacy, Infectious Diseases, Pharmacokinetics +17

Clesrovimab for Prevention of RSV Disease in Healthy Infants

Heather J. Zar, Eric A. F. Simões, Shabir A. Madhi et al. · New England Journal of Medicine · 2025 · 47 citations

Pharmacy, Pediatrics, Pharmacotherapy +13

Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults

Jia Yao Phuah, Brian M. Maas, Aimin Tang et al. · Biomedicine & Pharmacotherapy · 2023 · 43 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants

Shabir A. Madhi, Eric A. F. Simões, Armando Acevedo et al. · The Journal of Infectious Diseases · 2024 · 38 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody <scp>MK</scp>‐1654 in healthy Japanese adults

Yuji Orito, Naoyuki Otani, Yuki Matsumoto et al. · Clinical and Translational Science · 2022 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14